1. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma 
Isabelle Opitz, MD, Martina Friess, MD vet, Peter Kestenholz, MD, Didier Schneiter, MD, Thomas Frauenfelder, MD, Thi Dan Linh Nguyen-Kim, MD, Burkhardt Seifert, PhD, Mir Alireza Hoda, MD, Walter Klepetko, MD, Rolf A. Stahel, MD, Walter Weder, MD 
Journal of Thoracic Oncology 
Volume 10, Issue 11, Pages (November 2015)
DOI: /JTO
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Kaplan overall survival (OS) time In months Including all patients intended to be treated with chemotherapy followed by extrapleural pneumonectomy (EPP). A, Comparison of response to chemotherapy using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria: median survival time 22 months (95% confidence interval [CI]: 17–26) with stable disease (SD) or partial response (PR) versus median survival time 14 months (95% CI: 9–18) with progressive disease (PD). Response data were only available for 128 patients of the intention to treat (ITT) group. B, Comparison of chemotherapy regimen applied: median survival time 21 months (95% CI: 15–26) with cisplatin/gemcitabine (cis/gem) versus median survival time 18 months (95% CI: 12–24) with cisplatin/pemetrexed (cis/pem).
Journal of Thoracic Oncology  , DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan–Meier curve overall survival (OS) time in months of patients treated with induction chemotherapy alone versus induction chemotherapy followed by extrapleural pneumonectomy (EPP). Median survival time 22 months (95% confidence interval [CI]: 20–24) with EPP versus median survival time 10 months (95% CI: 9–12) without EPP.
Journal of Thoracic Oncology  , DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Kaplan-Meier curve of overall survival (OS) in months of the multimodality prognostic score (including four variables: tumor volume pre-CTX > 500 ml, C-reactive protein level (CRP) pre-CTX > 30 mg/liter, nonepithelioid histology in pre-CTX biopsy, and progressive disease according to modified Response Evaluation Criteria in Solid Tumors [RECIST] criteria): A, Patients treated with induction chemotherapy followed by extrapleural pneumonectomy (EPP; Zurich). B, Patients of the intention to treat group (Zurich). C, Patients treated with induction chemotherapy followed by EPP (Vienna).
Journal of Thoracic Oncology  , DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions